» Articles » PMID: 20870406

Pattern of Care in Locally Advanced Breast Cancer: Focus on Local Therapy

Overview
Journal Breast
Publisher Elsevier
Specialties Endocrinology
Oncology
Date 2010 Sep 28
PMID 20870406
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Methods: The optimal treatment of locally advanced breast cancer (LABC) remains undetermined. We analyzed factors influencing local therapy in LABC in a pooled material including three large clinical series.

Results: Of a total of 787 patients, local therapy was given in 604, surgery in 184, radiotherapy in 69, and a combination thereof in 351. The use of local therapy was related to younger age, lower clinical T and N stage, no skin involvement and no progression during induction chemotherapy. The use of surgery was related to younger age, lower clinical T and N stage, no clinical skin involvement and response to induction chemotherapy. The use of postoperative radiotherapy was correlated with larger tumor size, higher number of positive lymph nodes, positive surgical margin, extracapsular lymph node extension, lymphatic vessel invasion and skin involvement.

Conclusions: The most frequent local therapy in LABC remains a combination of surgery and radiotherapy. Clinical and pathological characteristics influence the type of local treatment.

Citing Articles

Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition).

J Natl Cancer Cent. 2024; 4(2):107-127.

PMID: 39282589 PMC: 11390704. DOI: 10.1016/j.jncc.2023.12.001.


A prospective single arm cohort study: An analysis of the effectiveness of surgical treatment of locally advanced breast cancer.

Xu Y, Huang X, Chen C, Li Y, Zhou Y, Shen S Heliyon. 2024; 10(16):e36279.

PMID: 39247320 PMC: 11378890. DOI: 10.1016/j.heliyon.2024.e36279.


Prognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: a meta-analysis.

Qi X, Chen J, Wei S, Ni J, Song L, Jin C BMJ Open. 2023; 13(11):e074874.

PMID: 37996220 PMC: 10668253. DOI: 10.1136/bmjopen-2023-074874.


MYL5 as a Novel Prognostic Marker is Associated with Immune Infiltrating in Breast Cancer: A Preliminary Study.

Lv M Breast J. 2023; 2023:9508632.

PMID: 36846347 PMC: 9957649. DOI: 10.1155/2023/9508632.


Systemic Immune-Inflammation Index Is Superior to Neutrophil to Lymphocyte Ratio in Prognostic Assessment of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.

Jiang C, Lu Y, Zhang S, Huang Y Biomed Res Int. 2020; 2020:7961568.

PMID: 33381583 PMC: 7762645. DOI: 10.1155/2020/7961568.